HBVCure New
Meeting category
Date(s)
6 Nov 2019
Location
Toronto, Canada
Organizer

International Workshop on HBV Cure 2019

Related Enduring Materials

Enduring Materials
Program

The 6th edition of the International HBV Cure Workshop featured the world's most prominent and distinguished speakers that discussed the most current and trending issues in the field. 

 Wednesday, 6 November 2019

- 08:00
08:00 EDT
Welcome
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
Session 1: Review of Nucleoside analogue Stopping studies -
Chairs
David Wong
David Wong
-
Marion Peters
Marion Peters, MA
University of California, USA
08:10 EDT
Stopping Nucleos(t)ide Analogues: Clinical outcomes of HBs Loss, retreatment and flares
Pietro Lampertico, MD, PhD
University of Milan, Italy
08:25 EDT
Virological biomarkers in patients stopping Nucs
Florian van Bommel, MD
University Hospital Leipzig
08:40 EDT
Immunological response after stopping Nucs
Andre Boonstra
Andre Boonstra
Erasmus Medical Center, the Netherlands
Session 2: New Endpoints and Biomarkers -
Chairs
Robert Gish
Robert Gish
Robert G. Gish Consultants LLC
Scott Fung, MD, FRCPC
Toronto General Hospital, Toronto, Canada
09:20 EDT
Review of the FDA/EMA HBV Endpoints Meeting
Fabien Zoulim, MD, PhD
Lyon I University / Hospices Civils de Lyon / INSERM, France
09:35 EDT
Are HBcrAg, HBV RNA and anti-HBc Viable Biomarkers
Florian van Bommel, MD
University Hospital Leipzig
09:50 EDT
Are ALT Flares Associated with Improved Virological Clearance
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
Session 3: How to make immunology curative -
Chairs
Adam Gehring, PhD
Toronto Centre for Liver Disease, Canada
Georg Lauer
Georg Lauer
-
10:40 EDT
High Resolution of Exhausted T cells Ex Vivo in Chronic HBV Infection
Robert Thimme
Robert Thimme
University of Freiburg, Germany
10:55 EDT
Restoration of B cell Antibody Production in Chronic HBV patients
Mala Maini, MD, PhD
University College London, United Kingdom
11:10 EDT
Using FNAB to Investigate Intrahepatic Immunology
Adam Gehring, PhD
Toronto Centre for Liver Disease, Canada
11:25 EDT
Springbank RIG-I Agonist (Inarigivir)
placeholder3
Cheleas MacFarlane
Springbank Pharmaceuticals, Inc.
11:35 EDT
Gilead TLR8 agonist (GS-9688)
Simon Fletcher
Simon Fletcher
Gilead Sciences
11:45 EDT
Roche TLR-7 agonist
Lu Gao
Lu Gao
Roche, China
Session 4: Update on Viral Targets for HBV/HDV Therapy -
Chairs
Stephen Locarnini
Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)
Victorian Infectious Diseases Reference Laboratory
Raymond Schinazi
Raymond Schinazi, PhD, DSc
Emory University Center for AIDS Research (CFAR), USA
13:30 EDT
Mechanisms of cccDNA Maintenance and progress on Measurement
Massimo Levrero, MD
Hopital de la Croix-Rousse, France
13:45 EDT
Capsid inhibitor/cccDNA Inhibitor - Roche
Lu Gao
Lu Gao
Roche, China
13:55 EDT
Elimination of Residual HBV Replication and Prevention of cccDNA Generation with the Combination of NrtI and Core Inhibitor
Richard Colonno
Richard Colonno
Assemby Biosciences
14:05 EDT
sIRNA based therapy for Chronic Hepatitis B Treatment
Michael Biermer
Michael Biermer
Janssen
14:15 EDT
NAP's latest update in HBV and HDV
Andrew Vaillant
Andrew Vaillant
Replicor
14:25 EDT
MyrB + IFN effect on HBV & HDV
placeholder3
Stefan Urban
Heidelberg University Hospital
14:35 EDT
HDV Trials
Robert Gish
Robert Gish
Robert G. Gish Consultants LLC
Session 5: New Drug Combinations and Study Design -
Chairs
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
Fabien Zoulim, MD, PhD
Lyon I University / Hospices Civils de Lyon / INSERM, France
15:45 EDT
FDA Guidance on New Combinations
Poonam Mishra, MD, MPH, FAASLD
US Food and Drug Administration, United States
16:00 EDT
Hypothesized Synergies in new cobmination treatment beyond nucs
Jordan Feld, MD, MPH
Toronto Centre for Liver Disease, Canada
16:15 EDT
Study Design with New Combinations
Marion Peters, MD
Northwestern University, United States
17:15 EDT
Closure of workshop
Language